VOYAGER THERAPEUTICS INC. - COMMON STOCK

Voyager Reports Third Quarter 2025 Financial and Operating Results

10 نوفمبر 2025 08:01:00 بحسب Nasdaq GlobeNewswire

Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia

10 نوفمبر 2025 08:01:00 بحسب Nasdaq GlobeNewswire

Voyager to Present at Upcoming Investor Conferences

26 أغسطس 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Voyager Reports Second Quarter 2025 Financial and Operating Results

06 أغسطس 2025 16:01:00 بحسب Nasdaq GlobeNewswire

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

16 يوليو 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

10 يونيو 2025 07:00:51 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months Low: VOYAGER THERAPEUTICS INC. - COMMON STOCK

30 مايو 2025 09:48:31 بحسب NetDania Notify

NetDania - New 12 months Low: VOYAGER THERAPEUTICS INC. - COMMON STOCK

28 مايو 2025 14:51:04 بحسب NetDania Notify

Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication

15 مايو 2025 07:00:31 بحسب Nasdaq GlobeNewswire

Voyager Reports First Quarter 2025 Financial and Operating Results

06 مايو 2025 16:01:00 بحسب Nasdaq GlobeNewswire

Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting

28 أبريل 2025 16:30:00 بحسب Nasdaq GlobeNewswire

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

31 مارس 2025 07:00:47 بحسب Nasdaq GlobeNewswire

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

11 مارس 2025 16:01:00 بحسب Nasdaq GlobeNewswire

Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast

04 مارس 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease

03 مارس 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

25 فبراير 2025 07:00:01 بحسب Nasdaq GlobeNewswire

Voyager Provides Update on SOD1 ALS Gene Therapy Program

11 فبراير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Voyager to Present at Oppenheimer 25th Annual Healthcare Life Sciences Conference

06 فبراير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease

20 نوفمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Voyager Reports Third Quarter 2024 Financial and Operating Results

12 نوفمبر 2024 16:01:00 بحسب Nasdaq GlobeNewswire